Oncology Xagena
Zoledronic Acid ( Zometa ), an intravenous bisphosphonate, was shown to inhibit aromatase inhibitor-induced bone loss in postmenopausal women treated with Letrozole ( Femara ) in the adjuvant breast c ...
Bisphosphonates are routinely used in the treatment of metastatic bone disease from breast cancer to reduce pain and bone destruction. Zoledronic acid ( Zometa ) given by intravenous infusion has been ...
Role of aromatase inhibitors and Zoledronic acid ( Zometa ) as adjuvant treatment of premenopausal endocrine-responsive breast cancer patients is debated. Letrozole ( Femara ) has never been tested ...
